Beth Hecht Biography and Net Worth

Insider of Xeris Biopharma

Beth P. Hecht serves as the Chief Legal Officer and Corporate Secretary of Xeris Pharmaceuticals. She has over 25 years of experience as a corporate executive in the life science industry, most recently serving as Managing Director and Chief Legal and Administrative Oﬃcer for Auven Therapeutics, a global biotechnology and pharmaceutical private equity ﬁrm. Beth is currently a member of the Board of Directors of Iterum Therapeutics (Nasdaq: ITRM) and a member of both the Audit and Compensation Committees there. She was previously on the Board of Directors of Neos Therapeutics where she chaired the Nominating and Governance Committee.

Ms. Hecht is a graduate of Amherst College and Harvard Law School; she began her career as an attorney specializing in intellectual property and corporate transactions at Willkie Farr & Gallagher (NY) and later Kirkland & Ellis (NY). She has established and led legal, compliance, licensing, human resource, and security departments at companies including Durata Therapeutics, Sun Products, MedPointe Inc. (formerly Carter-Wallace Inc.), Warner Chilcott PLC, ChiRex Ltd., and Alpharma Inc.

What is Beth Hecht's net worth?: The estimated net worth of Beth Hecht is at least $14.26 million as of November 2nd, 2026. Hecht owns 1,086,130 shares of Xeris Biopharma stock worth more than $14,263,059 as of November 5th. This net worth evaluation does not reflect any other assets that Hecht may own. Learn More about Beth Hecht's net worth.
How do I contact Beth Hecht?: The corporate mailing address for Hecht and other Xeris Biopharma executives is 1375 West Fulton Street, Suite 1300, Chicago, IL, 60607. Xeris Biopharma can also be reached via phone at (844) 445-5704 and via email at [email protected]. Learn More on Beth Hecht's contact information.
Has Beth Hecht been buying or selling shares of Xeris Biopharma?: In the last ninety days, Beth Hecht has sold $412,577.06 in shares of Xeris Biopharma stock. Most recently, Beth Hecht sold 25,000 shares of the business's stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $10.23, for a transaction totalling $255,750.00. Following the completion of the sale, the insider now directly owns 1,086,130 shares of the company's stock, valued at $11,111,109.90. Learn More on Beth Hecht's trading history.
Who are Xeris Biopharma's active insiders?: Xeris Biopharma's insider roster includes Barbara-Jean Bormann-Kennedy (Director), James Brady (Director), Paul Edick (Insider), Dawn Halkuff (Director), Beth Hecht (Insider), John Johnson (Director), Kevin McCulloch (President and Chief Operating Officer), Marla Persky (Director), Steven Pieper (CFO), John Shannon, Jr. (Insider), and Jeffrey Sherman (Director). Learn More on Xeris Biopharma's active insiders.
Are insiders buying or selling shares of Xeris Biopharma?: In the last year, insiders at the sold shares 35 times. They sold a total of 755,883 shares worth more than $5,815,339.22. The most recent insider tranaction occured on November, 2nd when insider Steven Pieper sold 5,000 shares worth more than $51,150.00. Insiders at Xeris Biopharma own 4.4% of the company. Learn More about insider trades at Xeris Biopharma.
Information on this page was last updated on 11/2/2026.

Beth Hecht Insider Trading History at Xeris Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/2/2026	Sell	25,000	$10.23	$255,750.00	1,086,130
10/1/2026	Sell	16,666	$9.41	$156,827.06	1,111,130
9/1/2026	Sell	16,666	$8.49	$141,494.34	1,127,796
8/3/2026	Sell	16,666	$8.01	$133,494.66	1,144,462
7/1/2026	Sell	16,666	$8.03	$133,827.98	1,161,128
6/1/2026	Sell	16,667	$6.06	$101,002.02	1,176,506
5/1/2026	Sell	16,667	$6.23	$103,835.41	1,193,173
4/1/2026	Sell	16,667	$5.99	$99,835.33	1,209,840
3/2/2026	Sell	16,667	$6.25	$104,168.75	1,226,507
2/2/2026	Sell	16,667	$7.45	$124,169.15	1,243,174
1/2/2026	Sell	16,667	$7.43	$123,835.81	1,308,103
12/1/2025	Sell	16,667	$7.01	$116,835.67	1,320,176
11/11/2025	Sell	16,667	$7.40	$123,335.80	1,336,843
3/20/2025	Sell	40,000	$5.43	$217,200.00	1,353,510
2/19/2019	Buy	2,500	$10.00	$25,000.00

Beth Hecht Buying and Selling Activity at Xeris Biopharma

Xeris Biopharma Company Overview

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Today's Range

Now: $13.08

$12.32

$13.74

50 Day Range

MA: $9.49

$7.45

$13.08

2 Week Range

Now: $13.08

$5.25

$13.74

Volume

12,595,769 shs

Average Volume

2,237,899 shs

Market Capitalization

$2.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61